BPTES

BPTES is a selective inhibitor of Glutaminase GLS1 (KGA), which is found in the kidney and brain, and is positively regulated by myc and strongly expressed in many tumors and tumor cell lines. BPTES has a K(i) of approx. 3 microM. BPTES inhibits the allosteric activation caused by phosphate binding and promotes the formation of an inactive complex.

Product information

CAS Number: 314045-39-1

Molecular Weight: 524.68

Formula: C24H24N6O2S3

Synonym:

B PTES

BPTE-S

BPTES

BPTE S

Chemical Name: N,N'-((thiobis(ethane-2,1-diyl))bis(1,3,4-thiadiazole-5,2-diyl))bis(2-phenylacetamide)

Smiles: O=C(CC1=CC=CC=C1)NC1=NN=C(CCSCCC2=NN=C(NC(=O)CC3=CC=CC=C3)S2)S1

InChiKey: MDJIPXYRSZHCFS-UHFFFAOYSA-N

InChi: InChI=1S/C24H24N6O2S3/c31-19(15-17-7-3-1-4-8-17)25-23-29-27-21(34-23)11-13-33-14-12-22-28-30-24(35-22)26-20(32)16-18-9-5-2-6-10-18/h1-10H,11-16H2,(H,25,29,31)(H,26,30,32)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

BPTES (10 µM) exhibits inhibition of PDAC cell proliferation. BPTES preferentially slows growth of mutant IDH1 cells without inducing apoptosis. BPTES (10 µM) reduces glutaminase activity in both WT and mutant IDH1 expressing cells, diminishes glutamate and α-KG levels, and increases glycolytic intermediates while leaving total 2-HG levels unaffected. BPTES (10 µM) shows a clear synergistic anti-cancer effect with 10 μM of 5-FU in A549 and EKVX cell lines, and results in a growth reduction response not only in EKVX and A549 but also in most of the NSCLC cell lines. BPTES (10 µM) effectively reduces the levels of the metabolites of the TCA cycle, with no changes in the levels of metabolites in glycolysis and the pentose phosphate pathway. BPTES treatment reduces about 30% ATP production under normoxia, and an additional 10% reduction of ATP production is observed under hypoxia in EKVX.

In Vivo:

BPTES-NPs (BPTES nanoparticles, 1.2 mg BPTES in 100 µL nanoparticles, i.v.) significantly attenuates tumor growth in the patient-derived pancreatic orthotopic tumor model.

References:

1. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS, Kong M. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015 Jul 3;13:210. doi: 10.1186/s12967-015-0581-2. PubMed PMID: 26139106; PubMed Central PMCID: PMC4490757.
2. Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Y, Burma S, Scaglioni PP, Cantley LC, DeBerardinis RJ, Kimmelman AC, Lyssiotis CA, Boothman DA. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone. Cancer Metab. 2015 Oct 12;3:12. doi: 10.1186/s40170-015-0137-1. eCollection 2015. PubMed PMID: 26462257; PubMed Central PMCID: PMC4601138.
3. Lee SY, Jeon HM, Ju MK, Jeong EK, Kim CH, Park HG, Han SI, Kang HS. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget. 2016 Jan 11. doi: 10.18632/oncotarget.6879. [Epub ahead of print] PubMed PMID: 26771232.

Products are for research use only. Not for human use.